Cue Biopharma
CUE
100 hedge funds and large institutions have $89.2M invested in Cue Biopharma in 2022 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 28 increasing their positions, 28 reducing their positions, and 10 closing their positions.
120% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 10
48% more call options, than puts
Call options by funds: $1.11M | Put options by funds: $752K
11% more funds holding
Funds holding: 90 → 100 (+10)
0.07% more ownership
Funds ownership: 1.73% → 1.8% (+0.07%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 28
52% less capital invested
Capital invested by funds: $186M → $89.2M (-$96.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PM
Prosight Management
Dallas,
Texas
|
+$4.82M |
| 2 |
SMH
Sanders Morris Harris
Houston,
Texas
|
+$3.63M |
| 3 |
Renaissance Technologies
New York
|
+$2.93M |
| 4 |
BL
Bleichroeder LP
New York
|
+$2.49M |
| 5 |
CC
Carlson Capital
Dallas,
Texas
|
+$1.52M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$6.61M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$2.09M |
| 3 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
-$1.24M |
| 4 |
Rafferty Asset Management
New York
|
-$1.1M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$759K |
CUE Hedge Fund Activity: Q1 2022 in Review
100 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Cue Biopharma (CUE) for Q1 2022, worth a combined $89.2M — down 52% from $186M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new CUE positions and 10 closed out — a net gain of 12 holders — while 28 added to existing stakes and 28 trimmed.
The largest buyer was Prosight Management, adding an estimated $4.82M. The largest seller was State Street, cutting an estimated $6.61M.
- 100 institutional investors held Cue Biopharma (CUE) as of Q1 2022, up from 90 in Q4 2021.
- Funds reported $89.2M of Cue Biopharma stock for Q1 2022, down 52% quarter-over-quarter.
- 22 funds opened new Cue Biopharma positions in Q1 2022 and 10 closed out, a net change of +12 holders.
- The largest Cue Biopharma buyer in Q1 2022 was Prosight Management, an estimated $4.82M added.
- The largest Cue Biopharma seller in Q1 2022 was State Street, an estimated $6.61M sold.
Based on aggregated 13F filings for Q1 2022.